Hydrix Ltd (ASX:HYD)'s Gavin Coote outlines the business' medtech-centric vision for 2022 in his latest interview with Proactive. He says the company is working to develop products with cardiovascular and clinical technology that can improve patients' lives, while advancing Hydrix's services and venture offerings will become an even bigger component in 2022.
Hydrix looks to the future with cardio-centric medtech vision
